Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 101

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 101
---
 to limitations on transfer of your Depositary Shares.

Your Depositary Shares are
transferable on the books of the Depositary. However, the Depositary may close its books at any time or from time to time when it deems
expedient in connection with the performance of its duties. The Depositary may refuse to deliver, transfer or register transfers of your
Depositary Shares generally when our books or the books of the Depositary are closed, or at any time if we or the Depositary deems it
advisable to do so because of any requirement of law or government or governmental body, or under any provision of the deposit agreement,
or for any other reason.

We have no present intention to pay dividends on our Ordinary Shares in the foreseeable future and, consequently, your only opportunity to achieve a return on your investment during that time may be if the price of Depositary Shares appreciates.

We have no present intention
to pay dividends on our Ordinary Shares in the foreseeable future. Any determination by our Board of Directors to pay dividends will depend
on many factors, including our financial condition, results of operations, legal requirements and other factors. Accordingly, if the price
of the Depositary Shares falls in the foreseeable future and you sell your Depositary Shares, you will lose money on your investment,
without the likelihood that this loss will be offset in part or at all by cash dividends.

We are a non-accelerated filer, and the reduced reporting obligations applicable to non-accelerated filers may make our securities less attractive to investors.

We are a “non-accelerated
filer” under the rules of the SEC. For as long as we remain a “non-accelerated filer,” our independent registered public
accounting firm is not required to deliver an annual attestation report on the effectiveness of our internal control over financial reporting.
We will cease to be a non-accelerated filer if (a) the aggregate market value of our outstanding Ordinary Shares held by non-affiliates
as of the last business day of our most recently completed second fiscal quarter is $75 million or more and we reported annual net revenues
of greater than $100million for our most recently completed fiscal year or (b) the aggregate market value of our outstanding
Ordinary Shares held by non-affiliates as of the last business day of our most recently completed second fiscal quarter is $700million
or more, regardless of annual net revenues. If we cease to be a non-ac